explore -WSS

explore

author：Wikipedia 2025-09-30 17:03:49 - browse：62

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Health insurers say they are turning to AI to cut costs, improve care

WSS

Patient advocates debate FDA's accelerated approval process

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

First Opinion Podcast: What happens when kids become caregivers?

Food as medicine: Medically tailored meals may get standardized

Average age of first period drops to 11.9 years, study shows

What will save rural psychiatry services? Higher Medicaid payments

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Supreme Court mifepristone arguments center on docs' right to sue

How one medical school became remarkably diverse

Average age of first period drops to 11.9 years, study shows

United colonoscopy coverage change 'may cost lives,' doctors say

Lab trade group sues FDA to halt regulation of lab

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Adam's Biotech Scorecard: Do Sarepta's exon

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Decaf coffee targeted by food safety group under obscure FDA rule

focus

Why the world’s most expensive drug might be worth the price

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Supreme Court mifepristone arguments center on docs' right to sue

Average age of first period drops to 11.9 years, study shows

Scientists successfully use ultrasound imaging to map brain activity

AI used to predict Covid

hotspot

entertainment

hotspot

focus